Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) Conjugated With CD3/CD28-coated Microbeads in Patients With Relapsed or Refractory Hematological Malignancy

NCT00558675 is registered in ClinicalTrials.gov with Mirror Biologics, Inc. as lead sponsor.

NCT NCT00558675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00558675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) Conjugated With CD3/CD28-coated Microbeads in Patients With Relapsed or Refractory Hematological Malignancy
Lead sponsor
Mirror Biologics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2010
Completion date
March 31, 2013
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancy, leukemia, lymphoma, multiple myeloma